NPPC: FDA Stall Tactics Hurting U.S. Agriculture
The U.S. Food and Drug Administration’s (FDA) misrepresentation of a gene edited livestock research project is its latest stall tactic designed to rationalize a regulatory grasp on an emerging technology that must be regulated by the U.S. Department of Agriculture (USDA) if the United States is to maintain its global leadership position in agriculture.
“While countries like China, Canada, Brazil and Argentina are moving quickly on this advancement to gain competitive advantage, the United States is falling far behind because of the FDA’s precautionary regulatory approach,” said NPPC President David Herring, a hog farmer from Lillington, N.C. “Under FDA regulation, gene editing faces an impractical, lengthy and expensive approval process. Unless we move oversight to the USDA, we are ceding a technology that promises significant animal health benefits, including...
To Read Full Story Login Below.
Submit comment or question
Note: All comments are displayed with user's screen name. If screen name is not present, user's full name will be used. Please go to My Account to update your screen name.
Comment Policy: Urner Barry has made the comment feature available to encourage further discussion of our news stories. Defamatory or offensive comments, or comments deemed not relevant to the story will be removed, and if necessary, Urner Barry may restrict the right of individual subscribers to offer comments. In all cases, comments represent opinions of the poster only, and do not represent fact, news, opinions or estimates put forward by Urner Barry.
Email Address is required. Password is required.